PF-219,061
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| Routes of administration |
Nasal |
| Identifiers | |
|
|
| CAS Number | 710654-74-3  |
| PubChem (CID) | 9794475 |
| ChemSpider | 7970242 |
| Chemical and physical data | |
| Formula | C13H19NO2 |
| Molar mass | 221.295 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (verify) | |
PF-219,061 is a drug developed by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor.[1][2] It is under development as a potential medication for the treatment of female sexual dysfunction.[3][4]
See also[edit]
- ABT-670
- ABT-724
- Cabergoline
- Bremelanotide
- Flibanserin
- Intrinsa
- Melanotan II
- OSU-6162
- PF-592,379
- Pramipexole
- Tibolone
- UK-414,495
References[edit]
- ^ Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, Cook AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S. Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route. Bioorganic and Medicinal Chemistry Letters. 2007 Dec 15;17(24):6691-6. doi:10.1016/j.bmcl.2007.10.059 PMID 17976986
- ^ Brioni JD, Moreland RB. Dopamine D4 receptors and the regulation of penile erection. Drug Discovery Today: Therapeutic Strategies. 2006;3(4):599-604. doi:10.1016/j.ddstr.2006.10.006
- ^ Van Der Graaf et al. SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION. WIPO Patent WO/2003/051370, granted to Pfizer.
- ^ Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I. Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. Xenobiotica. 2009 Jul;39(7):523-33. PMID 19480558
